Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

1.44$0.07 5.11%
At close       04:00 PM   

Stock Snapshot

1.37
Prev. Close
1.41
Open
326.09M
Market Cap
3.52M
Number of Shares
1.4000
Day Low
1.5200
Day High
1.44
-
P/E Ratio
194.76M
Free Float in %
-0.11
EPS 2021
0.31
Book Value per Share
0.26
Cash Flow per Share
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc. (MTNB) stock rallied over 5.11% intraday to trade at $1.44 share on AMEX. The stock opened with a gain of % at $1.41 and touched an intraday high of $1.5200, rising 10.95% against the last close of $1.37. The stock went to a low of $1.4000 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-10$0.78$0.83$0.83$0.781,512,275
2021-09-03$0.81$0.80$0.83$0.8059,520,000
2021-09-02$0.81$0.81$0.82$0.8149,550,000
2021-09-01$0.80$0.82$0.83$0.7881,630,000
2021-08-31$0.82$0.80$0.82$0.8092,840,000
2021-08-30$0.85$0.80$0.85$0.80117,500,000
2021-08-27$0.80$0.80$0.85$0.7993,160,000
2021-08-26$0.82$0.80$0.82$0.78139,820,000
2021-08-25$0.76$0.84$0.85$0.76250,120,000
2021-08-24$0.71$0.74$0.75$0.7165,180,000
2021-08-23$0.69$0.72$0.72$0.6895,410,000
Matinas BioPharma Holdings, Inc.
1545 Route 206 South
Suite 302
Bedminster, NJ 07921
United States

http://www.matinasbiopharma.com
908 443 1860
Employees
21
Sector
Healthcare
Sales or Revenue
200000.00
Industry
Biotechnology
5Y Sales Change
-4.00
Fiscal Year Ends
2020-12-30

Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam